M. Bontenbal

4.9k total citations
66 papers, 3.4k citations indexed

About

M. Bontenbal is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, M. Bontenbal has authored 66 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 25 papers in Cancer Research and 15 papers in Genetics. Recurrent topics in M. Bontenbal's work include Cancer Treatment and Pharmacology (30 papers), Breast Cancer Treatment Studies (22 papers) and HER2/EGFR in Cancer Research (14 papers). M. Bontenbal is often cited by papers focused on Cancer Treatment and Pharmacology (30 papers), Breast Cancer Treatment Studies (22 papers) and HER2/EGFR in Cancer Research (14 papers). M. Bontenbal collaborates with scholars based in Netherlands, United States and Belgium. M. Bontenbal's co-authors include Jaap Verweij, Jacques Bonneterre, Carolien H. Smorenburg, John A. Foekens, J.G.M. Klijn, Robert Paridaens, Martine Piccart, J. Benraadt, Alexandra W. van den Belt‐Dusebout and Charles H. F. Gimbrère and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

M. Bontenbal

66 papers receiving 3.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Bontenbal Netherlands	31	2.1k	1.2k	667	575	480	66	3.4k
M. Namer France	29	2.4k 1.2×	1.4k 1.2×	612 0.9×	562 1.0×	982 2.0×	122	3.7k
A. Rubagotti Italy	32	1.6k 0.8×	1.2k 1.0×	1.3k 2.0×	638 1.1×	934 1.9×	131	3.7k
H.T. Mouridsen Denmark	22	1.4k 0.7×	1.3k 1.1×	634 1.0×	328 0.6×	362 0.8×	49	2.5k
Jean‐Marc Nabholtz France	24	1.9k 0.9×	1.3k 1.1×	1.2k 1.8×	508 0.9×	772 1.6×	54	3.2k
D C Tormey United States	32	2.1k 1.0×	1.1k 0.9×	644 1.0×	561 1.0×	718 1.5×	55	3.6k
Reena S. Cecchini United States	20	1.8k 0.8×	959 0.8×	1.1k 1.6×	393 0.7×	422 0.9×	49	2.9k
Mark L. Graham United States	26	2.2k 1.0×	1.7k 1.4×	1.1k 1.6×	1.3k 2.2×	574 1.2×	53	4.5k
W. Kwasny Austria	27	2.4k 1.2×	1.9k 1.6×	1.2k 1.8×	584 1.0×	727 1.5×	56	3.5k
David L. Ahmann United States	29	1.8k 0.9×	882 0.7×	710 1.1×	637 1.1×	460 1.0×	70	3.1k
T.J. Powles United Kingdom	34	1.9k 0.9×	1.2k 1.0×	1.1k 1.7×	777 1.4×	505 1.1×	73	3.7k

Countries citing papers authored by M. Bontenbal

Since Specialization

Citations

This map shows the geographic impact of M. Bontenbal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Bontenbal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Bontenbal more than expected).

Fields of papers citing papers by M. Bontenbal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Bontenbal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Bontenbal. The network helps show where M. Bontenbal may publish in the future.

Co-authorship network of co-authors of M. Bontenbal

This figure shows the co-authorship network connecting the top 25 collaborators of M. Bontenbal. A scholar is included among the top collaborators of M. Bontenbal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Bontenbal. M. Bontenbal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hamberg, Paul, Monique M.E.M. Bos, Hans J. Braun, et al.. (2011). Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial. Clinical Breast Cancer. 11(2). 103–113. 48 indexed citations

Gast, Marie‐Christine W., Marc Zapatka, Harm van Tinteren, et al.. (2011). Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer. Journal of Cancer Research and Clinical Oncology. 137(12). 1773–1783. 10 indexed citations

Swaak‐Kragten, Annemarie T., Johannes H.W. de Wilt, Paul Schmitz, M. Bontenbal, & Peter C. Levendag. (2009). Multimodality treatment for anaplastic thyroid carcinoma – Treatment outcome in 75 patients. Radiotherapy and Oncology. 92(1). 100–104. 93 indexed citations

Piccart, Martine, Tomasz Burzykowski, Marc Buyse, et al.. (2008). Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer. Journal of Clinical Oncology. 26(12). 1980–1986. 164 indexed citations

Gast, Marie‐Christine W., Harm van Tinteren, M. Bontenbal, et al.. (2008). Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients. BMC Cancer. 8(1). 389–389. 24 indexed citations

Hannemann, Juliane, Petra Kristel, Harm van Tinteren, et al.. (2006). Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy. British Journal of Cancer. 95(10). 1334–1341. 54 indexed citations

Rutgers, Emiel J., J.W.R. Nortier, M.K. Tuut, et al.. (2002). CBO-richtlijn 'behandeling van het mammacarcinoom'. Nederlandsch tijdschrift voor geneeskunde/Nederlands tijdschrift voor geneeskunde/NTvG-databank. 146(45). 2144–2151. 38 indexed citations

Smorenburg, Carolien H., Alex Sparreboom, M. Bontenbal, & Jaap Verweij. (2001). Combination chemotherapy of the taxanes and antimetabolites. European Journal of Cancer. 37(18). 2310–2323. 52 indexed citations

Smorenburg, Carolien H., M. Bontenbal, & Jaap Verweij. (2001). Capecitabine in Breast Cancer: Current Status. Clinical Breast Cancer. 1(4). 288–293. 14 indexed citations

10.

Smorenburg, Carolien H., et al.. (2000). Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients. Anti-Cancer Drugs. 11(10). 825–828. 55 indexed citations

11.

Curran, Desmond, Martine Piccart, J.C.J.M. de Haes, et al.. (2000). Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam Symptom Checklist. European Journal of Cancer. 36(12). 1488–1497. 49 indexed citations

12.

Bontenbal, M., et al.. (1998). Uptake and distribution of doxorubicin in hormone-manipulated human breast cancer cells in vitro. Breast Cancer Research and Treatment. 51(2). 139–148. 5 indexed citations

13.

Bontenbal, M., Maria Andersson, J. Wildiers, et al.. (1998). Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. British Journal of Cancer. 77(12). 2257–2263. 41 indexed citations

14.

Vries, Elisabeth G.E. de, Sjoerd Rodenhuis, H. Schouten, et al.. (1996). Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer. Breast Cancer Research and Treatment. 39(3). 307–313. 14 indexed citations

15.

Portengen, Henk, et al.. (1994). Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. British Journal of Cancer. 70(6). 1217–1223. 47 indexed citations

16.

Gerven, Joop van, et al.. (1994). Paclitaxel (Taxol) induces cumulative mild neurotoxicity. European Journal of Cancer. 30(8). 1074–1077. 66 indexed citations

17.

Gaast, Ate van der, M. Bontenbal, A.S.T. Planting, T.C. Kok, & T. A. W. Splinter. (1994). Phase II study of carboplatin and etoposide as a first line regimen in patients with metastatic breast cancer. Annals of Oncology. 5(9). 858–860. 6 indexed citations

18.

Leeuwen, Flora E. van, Alexandra W. van den Belt‐Dusebout, J. Benraadt, et al.. (1994). Risk of endometrial cancer after tamoxifen treatment of breast cancer. The Lancet. 343(8895). 448–452. 455 indexed citations

19.

Klijn, J.G.M., P.M.J.J. Berns, M. Bontenbal, & John A. Foekens. (1993). Growth Factors. Annals of the New York Academy of Sciences. 698(1). 85–101. 9 indexed citations

20.

Bontenbal, M., Anieta M. Sieuwerts, Harm Peters, et al.. (1990). Manipulation of cell cycle kinetics: Influence on the cytotoxicity of doxorubicin in human breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 37(6). 1097–1101. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact